In the REGARDS cohort, low hs-CRP levels were associated with a reduced risk of stroke, and CHD morbidity and mortality, while low LDL-c was not associated with protective effects.
ELISA-based measurement of apolipoprotein C-III on individual lipoproteins did not provide additional predictive information on development of coronary artery disease.
In high Lp(a)-associated CV risk patients, reduction of Lp(a) with PCSK9 inhibition lowered this risk, even at very low LDL-c levels.
A bempedoic acid/ezetimibe combination pill safely lowered LDL-c and hsCRP, on top of maximally tolerated statin treatment in high-risk ASCVD patients, more than the individual components of the pill.
Whilst lipidology relies mostly on routine laboratory investigations, special investigations are often required to describe specific lipids, lipoproteins and genetic problems. Prof. Marais gives an overview of those investigations.
Infusions of the HDL mimetics MDCO-216 and CER-001 did not reduce percent atheroma volume in the MILANO-PILOT and CARAT trials, respectively, although cholesterol efflux improved with MDCO-216.
An explorative study compared the timepoint at which outcome curves separate among 17 statin and 7 non-statin trials. Results suggest that futility should not be declared too early in trials.
Elevated Lp(a) is now officially considered a genetically determined risk factor for CVD in the USA. Chapman summarizes how Lp(a) is atherogenic and how novel therapies may target this process.
Prof. David Marais reviews the impact of various dietary lipids as they relate to the conventional lipoprotein profile in persons who do not have significant metabolic defects, as well as the impact on persons with metabolic disease.
A prespecified analysis of the ODYSSEY OUTCOME trial showed a bigger treatment effect of alirocumab with no adverse effects on measures of glycemia or new onset diabetes in patients with diabetes compared to those with normoglycemia or pre-diabetes.
In patients with HoFH, lomitapide led to a significant reduction of LDL-c levels and to achievement of EAS targets in many patients, while CV event rates correlated with LDL-c levels.
A subanalysis of the ORION-1 phase II trial showed that inclisiran reduced LDL-c in high CV risk patients, irrespective of presence of diabetes.